POLK — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL6366589	0.71	2/20
SCHEMBL7911252	0.67	2/20
SCHEMBL8176587	0.64	2/20
SCHEMBL3054875	0.63	2/20
SCHEMBL10394363	0.63	2/20
SCHEMBL10395154	0.63	2/20
SCHEMBL3179332	0.62	2/20
SCHEMBL5167656	0.60	2/20
SCHEMBL10407328	0.60	2/20
SCHEMBL454163	0.60	2/20
SCHEMBL7710665	0.60	2/20
SCHEMBL1287104	0.59	2/20
SCHEMBL1257476	0.59	2/20
SCHEMBL9179143	0.59	2/20
SCHEMBL8389556	0.58	2/20
SCHEMBL3420357	0.57	2/20
SCHEMBL4083649	0.57	2/20
SCHEMBL4083842	0.57	2/20
SCHEMBL4089868	0.57	2/20
SCHEMBL4600408	0.57	2/20

Clinical trials — most relevant to POLK by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A RCT of TNF and ENT in the Treatment of Long-term Prognosis With Hepatitis B-related HCC After Curative Resection	PHASE3	UNKNOWN
Intracameral Antibiotic Safety Study	PHASE3	SUSPENDED
Avelumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	PHASE2	UNKNOWN
Durvalumab for MSI-H or POLE Mutated Metastatic Colorectal Cancer	PHASE2	COMPLETED
I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers	PHASE1/PHASE2	NOT_YET_RECRUITING
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer	PHASE2	ACTIVE_NOT_RECRUITING
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer	PHASE2	RECRUITING
Gemcitabine and Irinotecan in Treating Patients With Cancer of Unknown Primary	PHASE2	COMPLETED
Everolimus in CDK12-Deficient Metastatic Colorectal Cancer (EVER-RECODE)	PHASE1/PHASE2	NOT_YET_RECRUITING
Clinical Study of EBV-LMP1 Targeted DNAzyme to Treat Nasopharyngeal Carcinoma	PHASE1/PHASE2	COMPLETED
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients	PHASE1/PHASE2	COMPLETED
A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors	PHASE1	COMPLETED
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas	PHASE1	COMPLETED
A Phase I Study of ABT-888, an Oral Inhibitor of Poly(ADP-ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors	PHASE1	COMPLETED
Tabectedin to Treat Children and Adolescents With Cancer	PHASE1	COMPLETED
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy With GenSci122 in Participants With Advanced Solid Tumors	PHASE1	RECRUITING
Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
ABT-888 Plus Metronomic Cyclophosphamide to Treat Cancer	PHASE1	COMPLETED
AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers	PHASE1	COMPLETED
PET Imaging of PARP Activity in Cancer	EARLY_PHASE1	UNKNOWN
Plant Extracted Natural Compounds Impact on Stage IV Breast Cancer Survival Time and Remission.	nan	UNKNOWN
Thymidine Kinase 1 in Risk Assessment for Hereditary Breast /Ovarian Cancer	nan	UNKNOWN
Spironolactone and XPB-1 Integrity in the TFIIH Complex	nan	ENROLLING_BY_INVITATION
Cohort of Tumors With POLE/D1 Mutation	nan	RECRUITING
DNA Damage & Repair Proteins In Patients With Atherosclerotic Coronary Artery Disease	nan	COMPLETED
The Impact of Myomectomy on IVF Outcomes	nan	NOT_YET_RECRUITING
A Proof of Concept Study for the DNA Repair Driven by the Mesenchymal Stem Cells in Critical COVID-19 Patients	nan	COMPLETED
Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a POLK binder may also engage these)

Protein	Name	Similarity
Q9QUG2	—	0.998	Q9QUG2 →
A3EWL3	—	0.990	A3EWL3 →
Q9D4G9	—	0.986	Q9D4G9 →
Q9QZ11	—	0.986	Q9QZ11 →
Q8GT06	—	0.985	Q8GT06 →
Q9FT70	—	0.985	Q9FT70 →
A4IF98	—	0.985	A4IF98 →
Q5FWF4	—	0.984	Q5FWF4 →
O93530	—	0.984	O93530 →
Q9VNX1	—	0.984	Q9VNX1 →
Q5SXJ3	—	0.984	Q5SXJ3 →
P12689	—	0.984	P12689 →
O09053	—	0.984	O09053 →
Q9JJN0	—	0.983	Q9JJN0 →
BLM	RecQ-like DNA helicase BLM	0.983	landscape →
WRN	Bifunctional 3'-5' exonuclease/ATP-dependent helicase WRN	0.983	landscape →
Q6JDV7	—	0.983	Q6JDV7 →
Q04692	—	0.983	Q04692 →
Q8BMI4	—	0.983	Q8BMI4 →
Q3T9Z9	—	0.983	Q3T9Z9 →
Q9W6K2	—	0.982	Q9W6K2 →
Q6NZP1	—	0.982	Q6NZP1 →
P14629	—	0.982	P14629 →
Q9W0P2	—	0.982	Q9W0P2 →
POLH	DNA polymerase eta	0.982	landscape →
Q9H9A7	—	0.982	Q9H9A7 →
D3ZA12	—	0.982	D3ZA12 →
F1NQJ3	—	0.982	F1NQJ3 →
L0N7N1	—	0.982	L0N7N1 →
Q9I920	—	0.982	Q9I920 →